Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Ibrance Joins Rival CDK4/6 Inhibitors In English Cancer Drugs Fund

Nov 28 2019

• By Francesca Bruce

money coins surrounded by pills tablets and capsules - Image — Ibrance To Enter Cancer Drugs Fund

Related Content

Ibrance v Kisqali: Quicker Novartis Discount Helps Cut UK NICE’s Timeline

Nov 17 2017

New Kisqali Combination Joins Verzenios In England’s Cancer Drugs Fund

Jul 17 2019

How Sustainable Is England’s Cancer Drugs Fund?

Nov 19 2019

Lilly Scores New Treatment Option For Verzenios In England

Apr 04 2019

Related Companies

Pfizer Inc.

Additional Topics

Europe United Kingdom Health Technology Assessment Market Access Policy Reimbursement Cancer BioPharmaceutical

More from Europe

More from Geography

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window